Executive Director, Channel Distribution Strategy

Executive Director, Channel Distribution Strategy 

The Executive Director, Channel Distribution Strategy is accountable for the design, implementation and evolution of channel distribution strategies across Skyhawk’s portfolio in North America. This individual will lead strategic planning considering country-specific regulations and policies, program sustainability, strategic alliances, patient and customer access, data, class of trade and setting of care. They will inform distribution service agreement design to support maximum access and distribution efficiency. They will leverage access and reimbursement expertise and considerations for mostly small molecules.

The ideal candidate combines deep pharmaceutical channel distribution expertise with strategic acumen, cross-functional leadership and the ability to navigate complex trade and emerging therapy models.

Responsibilities

• Serve as subject matter expert on evolving supply chain and distribution related laws, channel models, and strategic channel partner business models and capabilities


• Maintain a deep understanding of the Hospital, Specialty & Retail pharmacy channels; understand pharmacy and hospital capabilities and the competitive marketplace to ensure Skyhawk maintains an industry leading approach to patient support in specialty channels.


• Lead a team in designing scalable, innovative distribution strategies to maximize patient access and achieve corporate goals while considering financial impact, patient/ customer experience and strategic alliances


• Support recommendation with strong analytics and consideration of channel economics, active and pending policy (e.g. serialization, importation, state and federal pricing policy, etc.), reimbursement, setting of care, financial implications and patient access dynamics


• Collaborate with and ensure alignment across key stakeholders on channel distribution strategy development; Deliver recommendations to Senior Leadership and relevant, internal governing bodies and strategic teams


• Explore and develop direct to consumer distribution capabilities, market expertise and differentiations for Skyhawk’s portfolio programs


• Partner with commercial operation, market access and other teams to generate insights and inform commercialization planning, including forecasting, gross-to-net and operational build considerations

Requirements, Education, Experience & Skills:

• Bachelor’s degree in relevant field, Master’s Degree preferred


• Deep industry experience (15+ years) in trade and distribution in pharmaceutical or biotechnology companies


• Previous channel distribution experience with rare disease and small molecule is strongly preferred


• Expert knowledge of drug distribution channels including orphan drugs, 3PL, specialty distribution, specialty pharmacy, and Direct to Consumer channels.


• Previous solid leadership experience in building distribution strategies for orphan drug launch


• Proven track record of meeting or exceeding objectives & goals, both as an individual and as part of a team


• Proven ability to develop and lead strategic initiatives and projects both internally and with external consultant support.


• Relevant experience with distribution networks, new product launches, trade processes, and understanding of pharmaceutical supply chain.


• Demonstrated understanding of the US commercial and government healthcare and reimbursement environment, including product and fund flow, patient support and government programs


• Excellent communication skills with experience presenting to customers and internal leadership


• Demonstrated ability to successfully navigate cross-functional teams, influencing without direct authority, with the interpersonal skills to foster collaboration and succeed in a highly matrixed environment


• Ability to perform in a fast-paced environment, manage multiple priorities simultaneously, and work effectively across cross-functional teams

About Skyhawk

Skyhawk is committed to discovering, developing and commercializing small molecule therapeutics that modify RNA expression. We use our novel SkySTAR® platform (Skyhawk Small molecule Therapeutics for Alternative splicing of RNA) to develop drug candidates directed toward targets for some of the world’s most intractable diseases including neurological conditions, cancer, and traditionally “undruggable” targets.